More Life Sciences Headlines
TRENDLINES
Anthropic’s Claude Science app is coming for Kendall Square
Few places on the planet have more at stake in AI’s transformation and disruption of life sciences than the Massachusetts biomedical ecosystem.
Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
A resolution in arbitration puts Prime in its best position in years.
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis portfolio.
A year after distressed buyout, what’s become of Somerville’s Bluebird Bio?
David Meek bought the company last year for the pharma industry equivalent of loose change. The company was on the brink of bankruptcy. In 12 months, he says, it’s been transformed.
FDA drops enforcement against Whoop after it tweaks blood pressure feature
The agency’s updated wellness guidance remains ambiguous and poses risks to users, experts say.
AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal
Apogee’s lead drug, called zumilokibart, could be a long-lasting option for patients with a range of inflammatory diseases.
GSK to buy Cambridge-based Nuvalent, maker of targeted cancer drugs, for $10.6 billion
The deal is the latest in a run of biopharma acquisitions in recent months.
Moderna receives $50 million in push for Ebola vaccines
As the Ebola outbreak spreads in Congo and Uganda, health workers are rushing to provide supportive care.